Stargardt Disease clinical trials at UCLA
2 in progress, 0 open to eligible people
Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Sorry, in progress, not accepting new patients
The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are at least 8 years old. Enrollment is by invitation only. Funding Source - FDA OOPD
Los Angeles, California and other locations
ALK-001 on Stargardt Disease
Sorry, accepting new patients by invitation only
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
Los Angeles, California and other locations
Last updated: